Drawing for PRESCIDO

USPTO serial 97253726

PRESCIDO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
DUBIN, DAVID I
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PRESCIDO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRRALEIGH, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—
010Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for diagnosing and treating gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for use in hematology and in tissue and organ transplantation; medical apparatus and instruments for the diagnosis, prevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosis, prevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of immune system related diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of kidney diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention and treatment of hypertension; medical apparatus and instruments for the diagnosis, prevention and treatment of skin disorders; medical apparatus and instruments for use in urology; medical apparatus and instruments for ophthalmological use; medical apparatus and instruments for the diagnosis, prevention and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of respiratory diseases and asthma; radiological apparatus and instruments for medical use in the nature of radiological apparatus for medical purposes; genetic testing apparatus and instruments for medical use in the nature of genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus and instruments for medical use in the nature of electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations in the nature of medical apparatus for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments for DNA and RNA testing for medical use in the nature of apparatus for DNA and RNA testing for medical purposes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments for introducing pharmaceutical preparations into the human body in the nature of medical apparatus for introducing pharmaceutical preparations into the human bodyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 22, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 22, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 3, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 2, 2025EX5GSOU EXTENSION 5 GRANTED—
Oct 2, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 20, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 19, 2025EXT5SOU EXTENSION 5 FILED—
Nov 19, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 19, 2024EX4GSOU EXTENSION 4 GRANTED—
Nov 19, 2024EXT4SOU EXTENSION 4 FILED—
Nov 19, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 18, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 17, 2024EX3GSOU EXTENSION 3 GRANTED—
May 17, 2024EXT3SOU EXTENSION 3 FILED—
May 17, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 21, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 17, 2023EX2GSOU EXTENSION 2 GRANTED—
Nov 17, 2023EXT2SOU EXTENSION 2 FILED—
Nov 17, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 12, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 10, 2023EX1GSOU EXTENSION 1 GRANTED—
May 10, 2023EXT1SOU EXTENSION 1 FILED—
May 10, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 22, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 27, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 27, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 7, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 18, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 17, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 17, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 17, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022DOCKASSIGNED TO EXAMINER—
Feb 9, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 8, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance